Tags

Type your tag names separated by a space and hit enter

Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial.

Abstract

101 outpatients suffering from anxiety of non-psychotic origin (DSM-III-R criteria: agoraphobia, specific phobia, generalized anxiety disorder, and adjustment disorder with anxiety) were included in a 25-week multicenter randomized placebo-controlled double-blind trial with WS 1490, a special extract of kava-kava. In the main outcome criterion, the Hamilton Anxiety Scale (HAMA), there was a significant superiority of the test drug starting from week 8 on. WS 1490 was also found to be superior with respect to the secondary outcome variables. HAMA subscores somatic and psychic anxiety, Clinical Global Impression, Self-Report Symptom Inventory-90 Items revised, and Adjective Mood Scale. Adverse events were rare and distributed evenly in both groups. These results support WS 1490 as a treatment alternative to tricyclic antidepressants and benzodiazepines in anxiety disorders, with proven long-term efficacy and none of the tolerance problems associated with tricyclics and benzodiazepines.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Psychiatry, Jena University, Germany.

    Source

    Pharmacopsychiatry 30:1 1997 Jan pg 1-5

    MeSH

    Anti-Anxiety Agents
    Anxiety Disorders
    Double-Blind Method
    Female
    Humans
    Kava
    Male
    Middle Aged
    Outpatients
    Plant Extracts
    Plants, Medicinal
    Psychiatric Status Rating Scales
    Treatment Outcome

    Pub Type(s)

    Clinical Trial
    Journal Article
    Multicenter Study
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    9065962

    Citation

    Volz, H P., and M Kieser. "Kava-kava Extract WS 1490 Versus Placebo in Anxiety Disorders--a Randomized Placebo-controlled 25-week Outpatient Trial." Pharmacopsychiatry, vol. 30, no. 1, 1997, pp. 1-5.
    Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry. 1997;30(1):1-5.
    Volz, H. P., & Kieser, M. (1997). Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry, 30(1), pp. 1-5.
    Volz HP, Kieser M. Kava-kava Extract WS 1490 Versus Placebo in Anxiety Disorders--a Randomized Placebo-controlled 25-week Outpatient Trial. Pharmacopsychiatry. 1997;30(1):1-5. PubMed PMID: 9065962.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial. AU - Volz,H P, AU - Kieser,M, PY - 1997/1/1/pubmed PY - 1997/1/1/medline PY - 1997/1/1/entrez SP - 1 EP - 5 JF - Pharmacopsychiatry JO - Pharmacopsychiatry VL - 30 IS - 1 N2 - 101 outpatients suffering from anxiety of non-psychotic origin (DSM-III-R criteria: agoraphobia, specific phobia, generalized anxiety disorder, and adjustment disorder with anxiety) were included in a 25-week multicenter randomized placebo-controlled double-blind trial with WS 1490, a special extract of kava-kava. In the main outcome criterion, the Hamilton Anxiety Scale (HAMA), there was a significant superiority of the test drug starting from week 8 on. WS 1490 was also found to be superior with respect to the secondary outcome variables. HAMA subscores somatic and psychic anxiety, Clinical Global Impression, Self-Report Symptom Inventory-90 Items revised, and Adjective Mood Scale. Adverse events were rare and distributed evenly in both groups. These results support WS 1490 as a treatment alternative to tricyclic antidepressants and benzodiazepines in anxiety disorders, with proven long-term efficacy and none of the tolerance problems associated with tricyclics and benzodiazepines. SN - 0176-3679 UR - https://www.unboundmedicine.com/medline/citation/9065962/Kava_kava_extract_WS_1490_versus_placebo_in_anxiety_disorders__a_randomized_placebo_controlled_25_week_outpatient_trial_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-979474 DB - PRIME DP - Unbound Medicine ER -